October 2023 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2023-10-31

Businesses marketing unproven expensive stem cell treatments and exosome therapies for COVID-19 and Long Covid

Researchers have identified 38 businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies for preventing and treating COVID-19 even though these “interventions” have not been approved or authorized by national regulatory bodies and are not supported by convincing safety and efficacy data. The analysis, appearing in the journal Stem Cell Reports, also found

No Comments InCovid-19

PIER MARIA FORNASARI
2023-10-24

Clinical benefit for metastatic prostate cancer of Novartis Pluvicto™

Novartis presented data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen

No Comments InCANCER

PIER MARIA FORNASARI
2023-10-24

FDA frees Verve CRISP-R base editing clinical trial for Heterozygous Familial Hypercholesterolemia

The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S. since late last year as the FDA sought more details from Verve. Verve Therapeutics plans to soon start testing a gene editing therapy for heart disease in the U.S. after federal regulators lifted an order that had

No Comments InCRISPR GENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2023-10-21

New Gene Therapy Trials to fight Children Deafness

Researchers are testing an approach that involves replacing a mutated gene in the inner ears of children with severe hearing loss. Two companies have launched clinical trials to see if they can restore hearing to children with a rare type of genetic deafness. Akouos and Decibel Therapeutics, both based in Boston, are testing experimental therapies in

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2023-10-19

Researchers Design Gene Therapy That Can Effectively Target Glioblastoma

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body’s immune defenses against a cancer, have not been effective for GBM, in part because the tumor’s surrounding environment is largely impenetrable to assaults from the body’s immune system.

No Comments InCANCER GENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2023-10-13

NIH Scientists Unveil Detailed Cell Maps of the Human Brain and the Nonhuman Primate Brain

Incredibly detailed cell maps help pave the way for new generation of treatments A group of international scientists have mapped the genetic, cellular, and structural makeup of the human brain and the nonhuman primate brain. This understanding of brain structure, achieved by funding through the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies® Initiative, or

No Comments InBRAIN

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Archives: 2023-10-31

Businesses marketing unproven expensive stem cell treatments and exosome therapies for COVID-19 and Long Covid

Clinical benefit for metastatic prostate cancer of Novartis Pluvicto™

FDA frees Verve CRISP-R base editing clinical trial for Heterozygous Familial Hypercholesterolemia

New Gene Therapy Trials to fight Children Deafness

Researchers Design Gene Therapy That Can Effectively Target Glioblastoma

NIH Scientists Unveil Detailed Cell Maps of the Human Brain and the Nonhuman Primate Brain